Adventrx: Preclinical results for Thiovir show antiviral activity against avian flu, herpes, HIV

By E. Janene Geiss

Philadelphia, April 26 - Adventrx Pharmaceuticals, Inc. said Tuesday that preclinical results demonstrate broad antiviral activity of Thiovir against multiple subtypes of avian and human influenza A and human influenza B virus, two types of herpes simplex virus, HSV-1 and HSV-2 and multiple HIV strains.

The company plans to file an Investigational New Drug application with the Food and Drug Administration to begin a phase 1/2 clinical trial using Thiovir to treat HIV/AIDS in 2006, according to a company news release.

The company also said it is investigating development options for Thiovir to treat herpes infections and as a potential treatment for avian influenza.

Adventrx will present the results at the upcoming International Symposium on HIV and Emerging Infectious Diseases in Toulon, France. The abstract recently was accepted for oral presentation.

Thiovir is a broad spectrum antiviral drug that has been shown in preclinical tests to inhibit HIV, influenza A and herpes viruses. Thiovir is a pyrophosphate analogue reverse transcriptase inhibitor designed for oral delivery as a component of highly active antiretroviral therapy for HIV/AIDS. Thiovir is a prodrug for foscarnet that delivers both the active drug TPFA (thiophosphonoformate) and the active metabolite PFA (foscarnet).

Adventrx is a San Diego biopharmaceutical research and development company focused on introducing treatments for cancer and infectious diseases that surpass the performance and safety of existing drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.